Table 3.

Clinical and genetic parameters affecting time to distant recurrence, time to local recurrence, and overall survival in anaplastic glioma

Parameters	Patients (n = 86)	TTD		TTL		OS
		Median Months	P*	Median Months	P*	Median Months	P*
Age at diagnosis
<60 years	70	NR	.75	187	.15	NR	.058
≥60 years	16	NR		51		69
Preoperative KPS
≥80%	69	NR	.43	187	.55	NR	.25
<80%	17	NR		NR		87
Surgery
Total resection	38	NR	.14	NR	.13	NR	.014
Absence of total resection	48	NR		187		72
Radiological appearance
Diffuse	26	NR	.57	52	.017	50	.0035
Focal	60	NR		187		NR
Gd enhancement
Yes	63	NR	.57	187	.66	136	.75
No	23	NR		NR		NR
Ki-67 labeling index
<15%	35	NR	.0028	NR	.47	136	.16
≥15%	45	NR		187		76
CD133 expression
Low	76	NR	.0009	187	.022	NR	.0006
High	10	23		32		29
IDH1
Mutated	58	NR	<.0001	187	.0013	NR	<.0001
Wild-type	28	23		22		22
MGMT
Methylated	62	NR	.0011	187	.31	NR	.033
Unmethylated	24	NR		NR		44
1p19q loss
No	62	NR	.24	95	.0026	69	.0088
Yes	24	NR		187		NR
TP53 mutation
No	49	NR	.83	187	.18	NR	.35
Yes	37	NR		NR		72

Abbreviations: KPS, Karnofsky performance status; NR, not reached; OS, overall survival; TTD, time to distant recurrence; TTL,time to local recurrence.

*Log-rank test.